IL258150B - Methods for treating intraocular pressure with angiopoietin-1 receptor activators - Google Patents
Methods for treating intraocular pressure with angiopoietin-1 receptor activatorsInfo
- Publication number
- IL258150B IL258150B IL258150A IL25815018A IL258150B IL 258150 B IL258150 B IL 258150B IL 258150 A IL258150 A IL 258150A IL 25815018 A IL25815018 A IL 25815018A IL 258150 B IL258150 B IL 258150B
- Authority
- IL
- Israel
- Prior art keywords
- activators
- tie
- methods
- intraocular pressure
- treating intraocular
- Prior art date
Links
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 230000004410 intraocular pressure Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222481P | 2015-09-23 | 2015-09-23 | |
| PCT/US2016/053107 WO2017053566A1 (en) | 2015-09-23 | 2016-09-22 | Methods of treating intraocular pressure with activators of tie-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL258150A IL258150A (en) | 2018-05-31 |
| IL258150B true IL258150B (en) | 2021-06-30 |
Family
ID=58276474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL258150A IL258150B (en) | 2015-09-23 | 2018-03-15 | Methods for treating intraocular pressure with angiopoietin-1 receptor activators |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10952992B2 (enExample) |
| EP (3) | EP3352856B1 (enExample) |
| JP (3) | JP6959924B2 (enExample) |
| KR (1) | KR20180054677A (enExample) |
| CN (2) | CN113713101B (enExample) |
| AU (2) | AU2016326510C1 (enExample) |
| BR (1) | BR112018005499A2 (enExample) |
| CA (1) | CA2998673C (enExample) |
| ES (2) | ES2981607T3 (enExample) |
| IL (1) | IL258150B (enExample) |
| MX (2) | MX387804B (enExample) |
| MY (1) | MY194736A (enExample) |
| PH (1) | PH12018500658A1 (enExample) |
| SG (1) | SG10201912000WA (enExample) |
| WO (1) | WO2017053566A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| WO2017053566A1 (en) | 2015-09-23 | 2017-03-30 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
| EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
| US20210283051A1 (en) * | 2018-07-13 | 2021-09-16 | Mannin Research, Inc. | Ve-ptp inhibition in glaucoma |
| CA3137138A1 (en) * | 2019-04-18 | 2020-10-22 | EyePoint Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
| CA3138682A1 (en) | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| GB2589400A (en) * | 2019-06-24 | 2021-06-02 | Aerpio Pharmaceuticals Inc | Formulations of tie-2 activators and methods of use thereof |
| US11613534B2 (en) | 2019-10-29 | 2023-03-28 | EyePoint Pharmaceuticals, Inc. | Small molecule activators of Tie-2 |
| US20210212998A1 (en) * | 2020-01-08 | 2021-07-15 | Aerpio Pharmaceuticals, Inc. | Combinations of Tie-2 Activators and Prostaglandins and Uses Thereof |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US645503A (en) | 1899-05-11 | 1900-03-13 | Timothy Francis Crowley | Cutter-gage for ice-cream, & c. |
| US953924A (en) | 1909-06-28 | 1910-04-05 | Dow Wire & Iron Works | Sliding door. |
| US20030040463A1 (en) | 1996-04-05 | 2003-02-27 | Wiegand Stanley J. | TIE-2 ligands, methods of making and uses thereof |
| AU5154098A (en) | 1996-10-31 | 1998-05-22 | Duke University | Soluble tie2 receptor |
| US5980929A (en) | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
| US5919813C1 (en) | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
| HK1043537A1 (zh) | 1999-03-26 | 2002-09-20 | Regeneron Pharmaceuticals, Inc. | 通過tie2受體激活劑調節血管通透性 |
| US6455035B1 (en) | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| EP1046715A1 (en) | 1999-04-23 | 2000-10-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2 |
| US6897201B2 (en) * | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
| WO2003034990A2 (en) | 2001-10-25 | 2003-05-01 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
| WO2003084565A2 (en) | 2002-04-08 | 2003-10-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ve-ptp as regulator of ve-cadherin mediated processes or disorders |
| IL164799A0 (en) | 2002-04-25 | 2005-12-18 | Univ Connecticut | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| US7226755B1 (en) | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7507568B2 (en) | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| US8298532B2 (en) | 2004-01-16 | 2012-10-30 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
| ME02540B (me) | 2004-03-15 | 2017-02-20 | Janssen Pharmaceutica Nv | Modulatori optoidnih receptora |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| EP2361931B1 (en) | 2004-07-20 | 2017-12-06 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
| EP1819355A4 (en) | 2004-09-28 | 2009-08-12 | Genexel Sein Inc | METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| US7893040B2 (en) | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US20090123474A1 (en) | 2005-12-15 | 2009-05-14 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| PT1991275E (pt) | 2006-03-08 | 2015-02-03 | Archemix Llc | Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares |
| DE102006016426A1 (de) * | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20130023542A1 (en) | 2006-06-27 | 2013-01-24 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| CA2693383C (en) | 2006-10-27 | 2017-03-28 | Sunnybrook Health Sciences Center | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| CA2716347C (en) | 2008-02-21 | 2017-06-20 | Sequoia Pharmaceuticals, Inc. | Amino acid inhibitors of cytochrome p450 |
| WO2010081172A1 (en) | 2009-01-12 | 2010-07-15 | Akebia Therapeutics Inc. | Methods for treating vascular leak syndrome |
| WO2012047966A2 (en) | 2010-10-07 | 2012-04-12 | Akebia Therapeutics Inc. | Compositions and methods for treating ocular edema, neovascularization and related diseases |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| WO2010097800A1 (en) | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| CN102340993A (zh) | 2009-03-03 | 2012-02-01 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| ES2508290T3 (es) | 2009-03-03 | 2014-10-16 | Alcon Research, Ltd. | Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo |
| KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| CA2803675A1 (en) | 2010-07-12 | 2012-01-19 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| US20180092883A1 (en) | 2010-10-07 | 2018-04-05 | Aerpio Therapeutics, Inc. | Phosphatase inhibitors for treating ocular diseases |
| WO2012073627A1 (ja) | 2010-12-02 | 2012-06-07 | 丸善製薬株式会社 | Ｔｉｅ２活性化剤、血管内皮増殖因子（ＶＥＧＦ）阻害剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤、並びに医薬品組成物 |
| WO2013056233A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| US20130190324A1 (en) | 2011-12-23 | 2013-07-25 | The Regents Of The University Of Colorado, A Body Corporate | Topical ocular drug delivery |
| WO2013155512A2 (en) | 2012-04-13 | 2013-10-17 | The Johns Hopkins University | Treatment of ischemic retinopathies |
| RS62509B1 (sr) | 2012-07-13 | 2021-11-30 | Roche Glycart Ag | Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti |
| CA3012929C (en) | 2012-07-31 | 2023-01-17 | The Board Of Regents Of The University Of Texas System | Methods and compositions for in vivo induction of pancreatic beta cell formation |
| CN104755103A (zh) | 2012-10-11 | 2015-07-01 | 阿森迪斯药物眼科部股份有限公司 | 用于治疗眼病症的中和vegf的前药 |
| ES3023054T3 (en) | 2012-11-08 | 2025-05-29 | Clearside Biomedical Inc | Methods for the treatment of ocular disease in human subjects |
| EP2922572A1 (en) | 2012-11-23 | 2015-09-30 | AB Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| MY171945A (en) | 2013-03-15 | 2019-11-08 | Aerpio Therapeutics Inc | Compositions, formulations and methods for treating ocular diseases |
| ES2743509T3 (es) | 2013-04-11 | 2020-02-19 | Sunnybrook Res Inst | Métodos, usos y composiciones de agonistas de Tie2 |
| JP2016522250A (ja) | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用 |
| US20160137717A1 (en) | 2013-06-20 | 2016-05-19 | Gabriela Burian | Use of a vegf antagonist in treating choroidal neovascularisation |
| US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
| BR112016000282A2 (pt) | 2013-07-11 | 2017-12-12 | Novartis Ag | uso de antagonista de vegf em tratamento de retinopatia da prematuridade |
| BR112016000177A2 (pt) | 2013-07-11 | 2017-12-12 | Novartis Ag | usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta |
| EP3381940B1 (en) | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| TR201905773T4 (tr) | 2013-10-01 | 2019-05-21 | Sphingotec Gmbh | Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul. |
| US9592271B2 (en) | 2013-11-01 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
| US9994560B2 (en) * | 2014-03-14 | 2018-06-12 | Aerpio Therapeutics, Inc. | HPTP-β inhibitors |
| WO2015152415A1 (ja) | 2014-04-04 | 2015-10-08 | 株式会社ダイゾー | 吐出容器 |
| JP2015199733A (ja) * | 2014-04-04 | 2015-11-12 | 国立大学法人東北大学 | 眼圧降下剤 |
| US9719135B2 (en) | 2014-07-03 | 2017-08-01 | Mannin Research Inc. | Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| US20160082129A1 (en) | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| WO2017053566A1 (en) | 2015-09-23 | 2017-03-30 | Aerpio Therapeutics, Inc. | Methods of treating intraocular pressure with activators of tie-2 |
| CA3138682A1 (en) * | 2019-04-29 | 2020-11-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
-
2016
- 2016-09-22 WO PCT/US2016/053107 patent/WO2017053566A1/en not_active Ceased
- 2016-09-22 ES ES21191499T patent/ES2981607T3/es active Active
- 2016-09-22 CA CA2998673A patent/CA2998673C/en active Active
- 2016-09-22 CN CN202110932276.3A patent/CN113713101B/zh active Active
- 2016-09-22 AU AU2016326510A patent/AU2016326510C1/en active Active
- 2016-09-22 US US15/273,068 patent/US10952992B2/en active Active
- 2016-09-22 CN CN201680068508.2A patent/CN108290057A/zh active Pending
- 2016-09-22 EP EP16849594.3A patent/EP3352856B1/en active Active
- 2016-09-22 BR BR112018005499A patent/BR112018005499A2/pt not_active Application Discontinuation
- 2016-09-22 MX MX2018003542A patent/MX387804B/es unknown
- 2016-09-22 MY MYPI2018000423A patent/MY194736A/en unknown
- 2016-09-22 EP EP24169519.6A patent/EP4414032A3/en active Pending
- 2016-09-22 JP JP2018534502A patent/JP6959924B2/ja active Active
- 2016-09-22 EP EP21191499.9A patent/EP3977994B1/en active Active
- 2016-09-22 ES ES16849594T patent/ES2894802T3/es active Active
- 2016-09-22 KR KR1020187010228A patent/KR20180054677A/ko not_active Withdrawn
- 2016-09-22 SG SG10201912000WA patent/SG10201912000WA/en unknown
-
2018
- 2018-03-15 IL IL258150A patent/IL258150B/en active IP Right Grant
- 2018-03-22 MX MX2021010915A patent/MX2021010915A/es unknown
- 2018-03-23 PH PH12018500658A patent/PH12018500658A1/en unknown
-
2021
- 2021-01-15 US US17/150,430 patent/US11666558B2/en active Active
- 2021-10-08 JP JP2021165943A patent/JP7451472B2/ja active Active
-
2022
- 2022-04-20 AU AU2022202618A patent/AU2022202618B2/en active Active
-
2023
- 2023-04-21 US US18/304,511 patent/US12171751B2/en active Active
-
2024
- 2024-03-06 JP JP2024033979A patent/JP2024061772A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258150B (en) | Methods for treating intraocular pressure with angiopoietin-1 receptor activators | |
| IL259783A (en) | Methods of treatment of malignant diseases | |
| IL281318A (en) | A method for treating medulloblastoma with an EZH2 inhibitor | |
| GB201701673D0 (en) | Methods of well treatment | |
| PL3286311T3 (pl) | Sposób leczenia nowotworów złośliwych | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| EP3319619A4 (en) | Methods of treating colitis | |
| GB201410116D0 (en) | Method of treatment | |
| IL290069A (en) | Methods for treating eye conditions | |
| IL251769A0 (en) | Methods for treating eye conditions | |
| LT3280811T (lt) | Medžiagų dažymo būdas naudojant mikroorganizmus | |
| IL253028A0 (en) | treatment method | |
| GB201416832D0 (en) | Methods of treatment | |
| TWI560140B (en) | Method of making nanostructure | |
| ZA201607250B (en) | Drilling fluid and process of making the same | |
| PT3143195T (pt) | Tratamento enzimático de têxtil celulósico | |
| ZA201700027B (en) | Method of making super-hard articles | |
| GB201512139D0 (en) | Methods of treatment | |
| PT3191642T (pt) | Aquecimento de digestores hidráulicos | |
| GB201412869D0 (en) | Pressure controlled chamber | |
| TWI561166B (en) | Photosynthesis microfluidic chamber and photosynthesis method | |
| GB201421982D0 (en) | Method of treatment | |
| GB201421980D0 (en) | Method of treatment | |
| GB201415331D0 (en) | Method of treatment | |
| GB201414780D0 (en) | Method Of Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted |